Active Stocks
Fri Apr 19 2024 10:45:47
  1. Tata Steel share price
  2. 159.45 -0.34%
  1. Tata Motors share price
  2. 949.60 -2.24%
  1. Infosys share price
  2. 1,402.55 -1.27%
  1. ITC share price
  2. 424.10 1.23%
  1. Power Grid Corporation Of India share price
  2. 278.55 -0.59%
Business News/ News / World/  WHO says it will have advice on remdesivir in 3-4 weeks
BackBack

WHO says it will have advice on remdesivir in 3-4 weeks

A WHO panel will convene next week to look at all evidence of the effectiveness of the drug
  • WHO chief scientist Soumya Swaminathan said the U.S. FDA drug regulator does not appear to have taken the results of the global health body's study into account in giving approval
  • A bottle containing the drug Remdesivir is held by a health worker at the Institute of Infectology of Kenezy Gyula Teaching Hospital of the University of Debrecen in Debrecen, Hungary, (AP)Premium
    A bottle containing the drug Remdesivir is held by a health worker at the Institute of Infectology of Kenezy Gyula Teaching Hospital of the University of Debrecen in Debrecen, Hungary, (AP)

    GENEVA : The World Health Organization (WHO) said on Friday it is preparing guidelines on use of the drug remdesivir for COVID-19 and should be able to release them in three to four weeks.

    The United States has given full approval for remdesivir to treat infections, the first COVID-19 treatment to receive regulatory endorsement there.

    However, a large WHO study earlier this year on COVID-19 patients in hospital found that the drug probably had no effect on their survival rate.

    "We would anticipate that the guidelines will be available within three to four weeks," Janet Diaz, the WHO's top official for clinical care responses, told a news conference.

    A WHO panel will convene next week to look at all evidence of the effectiveness of the drug, made by Gilead Sciences , she added.

    WHO chief scientist Soumya Swaminathan said the U.S. FDA drug regulator does not appear to have taken the results of the global health body's study into account in giving approval.

    "We believe our results are very robust," Swaminathan said. "We hope that people who are doing treatment guidelines in other countries as well as regulators around the world will take note of our study results, in addition to the other evidence," she said.

    "Because you need to look at the global evidence for a drug, before you make decisions."

    Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

    This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.

    Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
    More Less
    Published: 23 Oct 2020, 10:30 PM IST
    Next Story footLogo
    Recommended For You
    Switch to the Mint app for fast and personalized news - Get App